HYDERABAD, India — Sai Life Sciences, an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated Unit VI, a dedicated manufacturing facility for veterinary Active Pharmaceutical Ingredients (APIs) in Bidar, India.
The new facility is located alongside Unit IV, the company’s flagship API site, and is designed exclusively for veterinary applications. Built to meet stringent global standards for safety, sustainability, and regulatory compliance, Unit VI strengthens Sai Life Sciences’ capabilities in providing efficient, scalable, and high-quality manufacturing solutions to animal health companies worldwide.
“This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability,” said Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences. “We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being.”
The global market for veterinary APIs is expanding, driven by increasing demand for animal medicines and advancements in animal healthcare. Sai Life Sciences’ investment aligns with its strategy to focus on niche, high-value pharmaceutical segments. With more than two decades of expertise, the company is recognized for advanced process capabilities, operational excellence, and stringent quality standards.
Unit VI integrates advanced technologies, robust supply chain management, and best-in-class safety practices, reinforcing the company’s role as a trusted partner in veterinary pharmaceutical manufacturing.
